Category Archives: Global News Feed

Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting

See original here:
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation.

See more here:
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer

Here is the original post:
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

REGULATED INFORMATION

See the rest here:
Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

Continue reading here:
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.

More here:
T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement

Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Gavreto is the first and only precision medicine approved in the European Union (EU) for the first-line treatment of people with RET fusion-positive advanced NSCLC.1

Go here to see the original:
European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer

Read the rest here:
Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.

Go here to read the rest:
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

Sandusky, OH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company has finalized terms for the acquisition of a license to a patented cannabis extraction process that will expand the company’s existing CBD intellectual property.

See the rest here:
PAOG Announces Pending Acquisition To Expand CBD IP Portfolio Scheduled For Early December